Protein Expression Laboratory

Targeted Protein Delivery Using Engineered Virus-like Particles

SAIC-Frederick Inc. researchers have developed self-assembling virus-like particles that can deliver therapeutic proteins against cancer and other diseases directly into target cells with near 100 percent efficiency.

Researchers have validated the performance of these particles in a human prostate cancer cell. The particles were at least twice as effective as current methods in delivering their protein payload, much less material was needed to deliver the desired amount of protein, and no genetic material accompanies protein delivery–offering multiple advantages compared to traditional in-vitro protein delivery systems.

This technology is being made available via collaboration with the National Cancer Institute (NCI), which owns the rights, for commercial development as a drug delivery system or as a highly efficient protein production and purification tool in laboratory research.

SAIC-Frederick is contracted to provide operations and technical support to NCI’s federal national laboratory in Frederick, Md.
– a government-owned, contractor-operated Federally Funded Research and Development Center. NCI owns patent rights to technologies developed under this contract.

SAIC-Frederick, Inc.
SAIC-Frederick, Inc., a wholly owned subsidiary of Science Applications International Corporation (SAIC), a Fortune 500® company, is the operations and technical support contractor at the National Cancer Institute at Frederick. This U.S. national laboratory is dedicated to rapidly translating basic research into new technologies for diagnosing, treating, and preventing cancer and AIDS.

Peptalk meeting, January 2011, San Diego
Targeted Protein Delivery Using Engineered Virus-like Particles

Deb K. Chatterjee
Associate Director, Protein Expression Laboratory, Advanced Technology Program, SAIC-Frederick, Inc., National Cancer Institute at Frederick, 1050 Boyles Street, Frederick, Maryland 21702

A highly effective protein delivery system based on virus-like particles (VLPs) has been developed. In addition to delivering various biologically active proteins into cytosol, we have shown that proteins, such as TRAIL and Interferon, can be displayed on the surface of VLPs and are biologically active. This approach could be used for delivering proteins to target cells in vitro and have potential for targeted delivery of therapeutic proteins in vivo. Funded by NCI Contract HHSN261200800001E.

Protein Expression Laboratory
Providing the tools for cloning, protein expression, purification, and detection technologies that help to overcome research obstacles…

The Protein Expression Laboratory develops, improves, and delivers protein-centric services. Our goal is to help client investigators achieve their research goals with the lowest possible cost in the shortest time. All PEL services are available individually as well as part of larger projects.

There will also be a presentation running at the NIH booth at BIO in DC June 27-30